10x Genomics (TXG) Accounts Payables (2018 - 2026)

10x Genomics' Accounts Payables history runs 9 years deep, the most recent figure standing at $17.4 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 73.07% year-over-year to $17.4 million; the TTM figure through Mar 2026 stood at $17.4 million (up 73.07% YoY), while the FY2025 annual figure was $12.7 million, down 1.36% from the prior year.
• Accounts Payables came in at $17.4 million for Q1 2026 at 10x Genomics, up from $12.7 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $29.3 million in Q1 2023 to a low of $10.1 million in Q1 2025.
• A 5-year average of $19.5 million and a median of $19.0 million in 2022 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables tumbled 50.2% in 2025 and jumped 73.07% in 2026, its largest moves.
• 10x Genomics' Accounts Payables stood at $21.6 million in 2022, then retreated by 27.14% to $15.7 million in 2023, then fell by 17.98% to $12.9 million in 2024, then decreased by 1.36% to $12.7 million in 2025, then surged by 36.85% to $17.4 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $17.4 million, $12.7 million, and $18.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison